NanoString Technologies has announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Trans-Arimidex, Tamoxifen, Alone or in Combination (TransATAC) studies. These results, which ...
NanoString Technologies, a provider of life science tools for translational research and molecular diagnostic products, has obtained the US Food and Drug Administration (FDA) 510(k) clearance for its Prosigna breast cancer prognostic gene ...
US-based NanoString Technologies has announced that its Prosigna Breast Cancer Prognostic Gene Signature Assay offers better prognostic information in endocrine treated patients with HR+ node negative disease. NanoString Technologies said ...
Tags: Prognostic Information, Medicine
US-based NanoString Technologies has announced that its Prosigna Breast Cancer Prognostic Gene Signature Assay offers better prognostic information in endocrine treated patients with HR+ node negative disease. NanoString Technologies said ...
Tags: Prognostic Information, Medicine
NanoString Technologies has reported positive results from a second validation study of its breast cancer assay based on the PAM50 gene expression signature. The CE-marked breast cancer assay is designed to provide a subtype ...
Tags: NanoString Technologies, breast cancer assay, PAM50 gene signature, study